Biopsy devices market seen reaching $4.95 billion by 2030

The global biopsy devices market is projected to rise from $3.53 billion in 2026 to $4.95 billion by 2030, driven by cancer screening, AI-assisted guidance and demand for minimally invasive diagnostics. North America held the largest regional share in 2025, while Asia-Pacific ranked second.

Why it matters: - Biopsy devices are central to early disease detection because they help doctors extract tissue or cell samples for laboratory analysis. - The market’s growth signals rising demand for diagnostic tools tied to cancer screening, precision oncology and outpatient care. - The report puts the market at a $4.94 billion to $4.95 billion opportunity by 2030, depending on the forecast year used in the release.

What happened: - The Business Research Company released a biopsy devices market study on July 29, 2026. - The market is projected to grow from $3.24 billion in 2025 to $3.53 billion in 2026, a 9.1% CAGR. - The report forecasts the market will reach $4.95 billion by 2030, at an 8.8% CAGR. - A free sample of the report is available here. - The full market report is available here.

The details: - Higher cancer screening rates, more diagnostic imaging centers and broader hospital diagnostic capabilities supported historical growth. - Increased use of biopsy procedures for earlier and more accurate diagnosis also contributed to expansion. - Forecast growth is tied to AI-assisted biopsy guidance systems, outpatient diagnostic demand, precision oncology growth, early disease detection priorities and new investment in biopsy technology. - Emerging trends include wider use of image-guided biopsy systems, greater preference for minimally invasive techniques, demand for precision sampling devices, automated biopsy guidance methods and a stronger focus on diagnostic accuracy. - Biopsy devices are used to collect cellular or tissue samples that are examined for disease, including cancer. - The devices help identify abnormal or malignant cells and support treatment planning. - Growing surgical volumes are expected to add to demand because biopsy devices are often used during procedures to collect specimens. - The American Med Spa Association reported in July 2025 that cosmetic procedure volumes in the U.S. rose 42.5% over four years, including 20.5 million non-surgical treatments and 17.4 million surgical procedures in 2024.

Between the lines: - The forecast suggests the market is shifting from basic sampling tools toward more precise, image-guided and automation-enabled systems. - Demand appears increasingly linked to where diagnostics happen, including outpatient settings and imaging centers, not just hospitals. - The report’s emphasis on precision oncology points to biopsy devices becoming more important as cancer care becomes more targeted.

What's next: - North America is expected to remain a major market, with Asia-Pacific continuing as the second-largest region. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and trend graphics. - More information is available on The Business Research Company.

The bottom line: - Biopsy devices are moving into a larger, more technology-driven market as providers push for earlier diagnosis, less invasive procedures and more accurate sampling.